Biogen (LSE:0R1B) - Stock Price, News & Analysis

0R1B Stock Overview

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally.

About the company

0R1B fundamental analysis
Snowflake Score
Valuation	4/6
Future Growth	2/6
Past Performance	0/6
Financial Health	5/6
Dividends	0/6

Rewards

Trading at 61.8% below our estimate of its fair value

Earnings are forecast to grow 17.65% per year

Analysts in good agreement that stock price will rise by 23.8%

Risk Analysis

Large one-off items impacting financial results

Profit margins (12.1%) are lower than last year (31%)

Biogen Inc. Competitors

Genus

LSE:GNS

UK£1.1b

Bioventix

AIM:BVXP

UK£229.7m

GSK

LSE:GSK

UK£62.2b

Hikma Pharmaceuticals

LSE:HIK

UK£4.2b

Price History & Performance

Summary of all time highs, changes and price drops for Biogen
Historical stock prices
Current Share Price	US$226.77
52 Week High	US$287.18
52 Week Low	US$189.59
Beta	-0.020
11 Month Change	6.63%
3 Month Change	5.23%
1 Year Change	-20.03%
33 Year Change	-34.84%
5 Year Change	-3.14%
Change since IPO	788.53%

Recent updates

Shareholder Returns

	0R1B	GB Biotechs	GB Market
7D	1.9%	-1.8%	-1.0%
1Y	-20.0%	-24.1%	7.3%

Return vs Industry: 0R1B exceeded the UK Biotechs industry which returned -24.1% over the past year.

Return vs Market: 0R1B underperformed the UK Market which returned 7.3% over the past year.

Price Volatility

Is 0R1B's price volatile compared to industry and market?
0R1B volatility
0R1B Average Weekly Movement	4.1%
Biotechs Industry Average Movement	5.7%
Market Average Movement	4.8%
10% most volatile stocks in GB Market	11.1%
10% least volatile stocks in GB Market	2.7%

Stable Share Price: 0R1B has not had significant price volatility in the past 3 months.

Volatility Over Time: 0R1B's weekly volatility (4%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
1978	7,570	Chris Viehbacher	www.biogen.com

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies.

Biogen Inc. Fundamentals Summary

How do Biogen's earnings and revenue compare to its market cap?
0R1B fundamental statistics
Market cap	US$33.30b
Earnings (TTM)	US$1.17b
Revenue (TTM)	US$9.66b

28.5x

P/E Ratio

3.4x

P/S Ratio

Is 0R1B overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
0R1B income statement (TTM)
Revenue	US$9.66b
Cost of Revenue	US$2.37b
Gross Profit	US$7.29b
Other Expenses	US$6.13b
Earnings	US$1.17b

Last Reported Earnings

Mar 31, 2024

Next Earnings Date

Aug 01, 2024

Earnings per share (EPS)	8.01
Gross Margin	75.49%
Net Profit Margin	12.07%
Debt/Equity Ratio	43.0%

How did 0R1B perform over the long term?

See historical performance and comparison

Biogen LSE:0R1B Stock Report